{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:59Z","timestamp":1792036859399,"version":"4.4.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Treatment for patients with multiple myeloma has experienced rapid development and improvement in recent years; however, patients continue to experience relapse, and multiple myeloma remains largely incurable. B-cell maturation antigen (BCMA) has been widely recognized as a promising target for treatment of multiple myeloma due to its exclusive expression in B-cell linage cells and its critical role in the growth and survival of malignant plasma cells. Here, we introduce STI-8811, a BCMA-targeting antibody\u2013drug conjugate (ADC) linked to an auristatin-derived duostatin payload via an enzymatically cleavable peptide linker, using our proprietary C-lock technology. STI-8811 exhibits target-specific binding activity and rapid internalization, leading to G2\/M cell-cycle arrest, caspase 3\/7 activation, and apoptosis in BCMA-expressing tumor cells in vitro. Soluble BCMA (sBCMA) is shed by multiple myeloma cells into the blood and increases with disease progression, competing for ADC binding and reducing its efficacy. We report enhanced cytotoxic activity in the presence of high levels of sBCMA compared with a belantamab mafodotin biosimilar (J6M0-mcMMAF). STI-8811 demonstrated greater in vivo activity than J6M0-mcMMAF in solid and disseminated multiple myeloma models, including tumor models with low BCMA expression and\/or in large solid tumors representing soft-tissue plasmacytomas. In cynomolgus monkeys, STI-8811 was well tolerated, with toxicities consistent with other BCMA-targeting ADCs with auristatin payloads in clinical studies. STI-8811 has the potential to outperform current clinical candidates with lower toxicity and higher activity under conditions found in patients with advanced disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>STI-8811 is a BCMA-targeting ADC carrying a potent auristatin derivative. We report unique binding properties which maintain potent cytotoxic activity under sBCMA-high conditions that hinder the clinical efficacy of current BCMA-targeting ADC candidates. Beyond disseminated models of multiple myeloma, we observed efficacy in solid tumor models of plasmacytomas with low and heterogenous BCMA expressions at a magnitude and duration of response exceeding that of clinical comparators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0413","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:45:01Z","timestamp":1726652701000},"page":"2660-2672","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preclinical Evaluation of STI-8811, a Novel Antibody\u2013Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4202-5918","authenticated-orcid":false,"given":"Aaron D.","family":"Springer","sequence":"first","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7996-6047","authenticated-orcid":false,"given":"Rengang","family":"Wang","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-7673","authenticated-orcid":false,"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4159-1171","authenticated-orcid":false,"given":"Qinyi","family":"Du","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8286-2955","authenticated-orcid":false,"given":"Willie","family":"Pi","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8492-8335","authenticated-orcid":false,"given":"Austin Q.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9958-6782","authenticated-orcid":false,"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"},{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9478-8343","authenticated-orcid":false,"given":"Alisher","family":"Khasanov","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2253-7798","authenticated-orcid":false,"given":"Tong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1843-1565","authenticated-orcid":false,"given":"Zheng","family":"Yan","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6819-6574","authenticated-orcid":false,"given":"Yufeng","family":"Hong","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-1876","authenticated-orcid":false,"given":"Heyue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6949-1898","authenticated-orcid":false,"given":"Yanliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-4931","authenticated-orcid":false,"given":"Lisa","family":"Kerwin","sequence":"additional","affiliation":[{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7840-9372","authenticated-orcid":false,"given":"Lingna","family":"Li","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0234-7253","authenticated-orcid":false,"given":"Henry","family":"Ji","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"},{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0336-8299","authenticated-orcid":false,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Levena BioPharma, San Diego, California. 1"},{"name":"Sorrento Therapeutics Inc., San Diego, California. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"2026031614531256600_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Medical progress: multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"2026031614531256600_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"2026031614531256600_bib3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026031614531256600_bib4","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","article-title":"Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods","volume":"35","author":"Corre","year":"2021","journal-title":"Leukemia"},{"key":"2026031614531256600_bib5","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026031614531256600_bib6","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1111\/cas.15163","article-title":"Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine","volume":"112","author":"Shimazu","year":"2021","journal-title":"Cancer Sci"},{"key":"2026031614531256600_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev-med-112017-091045","article-title":"New drugs in multiple myeloma","volume":"70","author":"Kunacheewa","year":"2019","journal-title":"Annu Rev Med"},{"key":"2026031614531256600_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/ph16040590","article-title":"Antibody\u2013drug conjugates for multiple myeloma: just the beginning, or the beginning of the end?","volume":"16","author":"Ray","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026031614531256600_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026031614531256600_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2848","article-title":"Sequencing of myeloma therapy: finding the right path among many standards","volume":"39","author":"Rajkumar","year":"2021","journal-title":"Hematol Oncol"},{"key":"2026031614531256600_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"2026031614531256600_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"2026031614531256600_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"2026031614531256600_bib14","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026031614531256600_bib15","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","article-title":"Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells","volume":"178","author":"Darce","year":"2007","journal-title":"J Immunol"},{"key":"2026031614531256600_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-065X.2010.00924.x","article-title":"The immortality of humoral immunity","volume":"236","author":"Elgueta","year":"2010","journal-title":"Immunol Rev"},{"key":"2026031614531256600_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"2026031614531256600_bib18","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2026031614531256600_bib19","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"2026031614531256600_bib20","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood"},{"key":"2026031614531256600_bib21","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2026031614531256600_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"2026031614531256600_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"2026031614531256600_bib24","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"2026031614531256600_bib25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust isolation of malignant plasma cells in multiple myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"key":"2026031614531256600_bib26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/ajh.26628","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am J Hematol"},{"key":"2026031614531256600_bib27","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3390\/cancers13122853","article-title":"Bispecific t cell engagers for the treatment of multiple myeloma: achievements and challenges","volume":"13","author":"Alhallak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026031614531256600_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"key":"2026031614531256600_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-319-40320-5_12","article-title":"Role of the immune response in disease progression and therapy in multiple myeloma","volume":"169","author":"Lee","year":"2016","journal-title":"Cancer Treat Res"},{"key":"2026031614531256600_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026031614531256600_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"2026031614531256600_bib32","first-page":"1210","article-title":"In vivo bioluminescent imaging of mammary tumors using IVIS spectrum","volume":"26","author":"Lim","year":"2009","journal-title":"J Vis Exp"},{"key":"2026031614531256600_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026031614531256600_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"key":"2026031614531256600_bib35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2214\/ajr.183.4.1830929","article-title":"Spectrum of imaging findings in abdominal extraosseous myeloma","volume":"183","author":"Patlas","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"2026031614531256600_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026031614531256600_bib37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bjh.16673","article-title":"Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients","volume":"192","author":"Jew","year":"2021","journal-title":"Br J Haematol"},{"key":"2026031614531256600_bib38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"key":"2026031614531256600_bib39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/PAS.0000000000001459","article-title":"Genetic basis of extramedullary plasmablastic transformation of multiple myeloma","volume":"44","author":"Liu","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2026031614531256600_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026031614531256600_bib41","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"2026031614531256600_bib42","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/ijms20051248","article-title":"The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026031614531256600_bib43","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"2026031614531256600_bib44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2026031614531256600_bib45","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026031614531256600_bib46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med Nat Res"},{"key":"2026031614531256600_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-139040","article-title":"Biallelic loss of BCMA triggers resistance to anti-BCMA car T cell therapy in multiple myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"2026031614531256600_bib48","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2019-129088","article-title":"T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0413\/3498493\/crc-24-0413.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2660\/3506130\/crc-24-0413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2660\/3506130\/crc-24-0413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:21Z","timestamp":1773687201000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/10\/2660\/749046\/Preclinical-Evaluation-of-STI-8811-a-Novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0413","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27210440","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210449","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762301","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762295","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727650","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31762292","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210431","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210452","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210455","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210443","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210446","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210434","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210437","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27210458","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7489964","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}